E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• E2F transcription factors (E2Fs) regulate cell cycle, apoptosis, and differentiation, impacting tumorigenesis.
• The precise roles of E2Fs in lung adenocarcinoma (LUAD) are not fully understood.
• Understanding E2F involvement is crucial for identifying new therapeutic targets and prognostic markers in LUAD.

Purpose of the Study:

• To investigate the specific roles and prognostic significance of E2F transcription factors in lung adenocarcinoma (LUAD).
• To identify potential biomarkers for overall survival (OS) and progression-free survival (PFS) in LUAD patients.
• To explore the functional mechanisms of E2F7 in LUAD progression, invasion, and metastasis.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) data and multiple databases (TIMER, cBioportal, GEPIA, LinkedOmics, CancerSEA) for comprehensive analysis.
• Performed mRNA expression, mutational analysis, prognostic modeling, clinical correlation, and pathway analyses.
• Validated findings using immunohistochemistry (IHC) to confirm E2F7 expression and correlation with LUAD characteristics.

Main Results:

• E2F transcription factor 7 (E2F7) was identified as a significant prognostic factor for overall survival (OS) in LUAD patients.
• E2F7 expression correlated positively with advanced tumor stage (p-TNM stage) and larger tumor size.
• E2F7 was found to be upregulated in LUAD tissues compared to paracancerous tissues and associated with DNA repair, cell cycle, and damage pathways.

Conclusions:

• E2F7 is significantly associated with prognosis (OS and PFS) in lung adenocarcinoma (LUAD).
• E2F7 expression levels correlate with tumor stage and size, suggesting a role in LUAD progression.
• E2F7 emerges as a potential prognostic biomarker for lung adenocarcinoma (LUAD).